2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
Home > Glaucoma > PreserFlo MicroShunt shows short-term benefit in refractory childhood glaucoma

PreserFlo MicroShunt shows short-term benefit in refractory childhood glaucoma

Ophthalmology 360

Key Takeaways

  1. PreserFlo MicroShunt implantation reduced intraocular pressure and medication use in children with refractory glaucoma.
  2. Surgical success rates declined over time, with only one-third of eyes maintaining success at 24 months.

Implantation of the PreserFlo MicroShunt significantly reduced intraocular pressure (IOP) and medication use in children with refractory glaucoma, according to a study. Investigators, however, did report declining long-term success rates beyond 12 months.

The retrospective study included 34 eyes from 27 children who underwent PreserFlo MicroShunt implantation and had refractory glaucoma with inadequate IOP control despite prior glaucoma surgery and maximal medical therapy. Mean follow-up was approximately 15 months.

Mean IOP decreased from 24.29 mmHg before surgery to 17.95 mmHg after surgery. The average number of IOP-lowering medications decreased from 3.0 to 0.9. Overall success was achieved in 61.7% of eyes, with 50% meeting criteria for complete success without medications.

Researchers found that the proportion of eyes maintaining successful IOP control declined over time, with success rates falling to 53% at 12 months and 33% at 24 months.

Reference

Imtirat A, Abu Rabia-Huleihel M, et al. Outcomes of the PreserFlo MicroShunt in Refractory Childhood Glaucoma. J Glaucoma. 2026;doi: 10.1097/IJG.0000000000002720. Epub ahead of print. PMID: 42148852.

Related Content